Pharo A - Search Results

1

Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.

Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G. Aurlien E, et al. Among authors: pharo a. Bone Marrow Transplant. 1998 May;21(9):873-8. doi: 10.1038/sj.bmt.1701192. Bone Marrow Transplant. 1998. PMID: 9613778

2

Purging of tumor cells from leukapheresis products: experimental and clinical aspects.

Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O. Kvalheim G, et al. Among authors: pharo a. J Hematother. 1996 Aug;5(4):427-36. doi: 10.1089/scd.1.1996.5.427. J Hematother. 1996. PMID: 8877718 Review.

3

[High-dose therapy of cancer with CD34 positive cells as stem cell support].

Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB. Kvalheim G, et al. Among authors: pharo a. Tidsskr Nor Laegeforen. 1996 Sep 10;116(21):2542-6. Tidsskr Nor Laegeforen. 1996. PMID: 8928121 Norwegian.

4

Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.

Kvalheim G, Fodstad O, Pihl A, Nustad K, Pharo A, Ugelstad J, Funderud S. Kvalheim G, et al. Among authors: pharo a. Cancer Res. 1987 Feb 1;47(3):846-51. Cancer Res. 1987. PMID: 3492268

5

Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow.

Myklebust AT, Godal A, Juell S, Pharo A, Fodstad O. Myklebust AT, et al. Among authors: pharo a. Cancer Res. 1994 Jan 1;54(1):209-14. Cancer Res. 1994. PMID: 7505198

6

Eradication of small cell lung cancer cells from human bone marrow with immunotoxins.

Myklebust AT, Godal A, Pharo A, Juell S, Fodstad O. Myklebust AT, et al. Among authors: pharo a. Cancer Res. 1993 Aug 15;53(16):3784-8. Cancer Res. 1993. PMID: 8393381

7

Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.

Myklebust AT, Pharo A, Fodstad O. Myklebust AT, et al. Among authors: pharo a. Br J Cancer. 1993 Jun;67(6):1331-6. doi: 10.1038/bjc.1993.246. Br J Cancer. 1993. PMID: 8390285 Free PMC article.

8

Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis.

Myklebust AT, Beiske K, Pharo A, Davies CD, Aamdal S, Fodstad O. Myklebust AT, et al. Among authors: pharo a. Br J Cancer Suppl. 1991 Jun;14:49-53. Br J Cancer Suppl. 1991. PMID: 1645572 Free PMC article.

9

The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.

Egge KH, Barratt-Due A, Nymo S, Lindstad JK, Pharo A, Lau C, Espevik T, Thorgersen EB, Mollnes TE. Egge KH, et al. Among authors: pharo a. Clin Exp Immunol. 2015 Sep;181(3):457-67. doi: 10.1111/cei.12645. Epub 2015 Jul 19. Clin Exp Immunol. 2015. PMID: 25907631 Free PMC article.

10

Complement C5a is a key mediator of meconium-induced neutrophil activation.

Castellheim A, Pharo A, Fung M, Saugstad OD, Mollnes TE. Castellheim A, et al. Among authors: pharo a. Pediatr Res. 2005 Feb;57(2):242-7. doi: 10.1203/01.PDR.0000150725.78971.30. Epub 2004 Dec 7. Pediatr Res. 2005. PMID: 15585680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters